Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Provention’s Therapy Delays Onset By Three Years

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Sanofi logo
Sanofi has exited Type 1 diabetes research, but retains a large commercial infrastructure in the US and worldwide. • Source: Shutterstock

Sanofi has entered into an alliance with Provention Bio for the US commercialization of teplizumab, a potential gamechanger in the field of type 1 diabetes which has shown in studies it can delay onset of the disease by three years.

The deal is an interesting development for Sanofi, which in recent years has de-prioritized its former blockbuster insulin brands. It...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip